NCI Affordable Cancer Technologies Program
CGH Program/Initiative Type: Cancer Research and Research Networks
Two-thirds of cancer deaths occur in low- and middle-income countries (LMICs). CGH supports the development and validation of affordable technology to increase access to cancer prevention, screening, detection, diagnosis, and treatment in LMICs, especially in rural areas with limited healthcare infrastructure.
Affordable Portable Technologies
We support development and validation of affordable, portable technologies with the potential to increase early detection, diagnosis, and non-invasive or minimally invasive treatment of cancer. Many existing technologies have the potential to be developed into affordable, point-of-care (POC) versions useful in resource-limited settings. Examples of possible technologies include in-vitro diagnostics, imaging tools, and devices for treatment modalities such as cryotherapy or photodynamic therapy.
In addition, we are interested in telemedicine approaches that leverage mobile phone technology in cancer prevention and treatment for patients. We are also developing strategies to support mobile health (mHealth) initiatives for LMICs to assist with patient follow-up and case management in cancer care.
Funding Opportunities
We want to increase the availability of affordable, portable technologies for cancer diagnosis, imaging, and treatment in LMICs. To do this, we have worked with other NCI divisions, the Small Business Innovation Research (SBIR) program, and other offices and centers to publish a Request for Application (RFA): Cancer Detection, Diagnosis, and Treatment Technologies for Global Health.
This program supports the development and validation of technologies with the potential to increase early detection, diagnosis, and non-invasive or minimally invasive treatment of cancer. Of particular emphasis is the development of affordable, portable point-of-care technologies for resource-constrained settings.
Contact
For any additional information about our affordable technology development programs, please email Paul Pearlman at paul.pearlman@nih.gov.